Global point of care
Malaria remains a significant global health challenge, killing approximately 597,000 and impacting 263 million people annually.1 Despite these staggering numbers, progress is continuing.
Achieving malaria eradication requires a combination of proven interventions and groundbreaking innovations in diagnostics and treatment. By leveraging advanced rapid diagnostic tests (RDTs) and addressing asymptomatic cases, we can move closer to a malaria-free world. This comprehensive approach not only aims to eliminate malaria but also protects vulnerable populations and ensure equitable healthcare access.
The World Health Organization (WHO) has set an ambitious goal to reduce malaria cases and deaths by at least 90% by 2030. This target isn’t just possible; it’s crucial. By combining proven interventions with new innovations, we could achieve malaria elimination.
Malaria presents several significant challenges that require a multifaceted approach:
Today, Abbott’s RDTs have high sensitivity and low time to result. These tests enable healthcare workers to quickly and reliably identify symptomatic cases, ensuring prompt treatment and reducing the risk of the disease spreading further.5 Every second counts. These technologies offer real hope to millions at risk.
are delivering fast, reliable diagnostics with superior accuracy and sensitivity, transforming malaria diagnosis
is crucial for those with symptoms, especially in remote, vulnerable communities
provide a broad portfolio of tests for high-transmission settings
Today, Abbott’s RDTs have high sensitivity and low time to result. These tests enable healthcare workers to quickly and reliably identify symptomatic cases, ensuring prompt treatment and reducing the risk of the disease spreading further.5 Every second counts. These technologies offer real hope to millions at risk.
are delivering fast, reliable diagnostics with superior accuracy and sensitivity, transforming malaria diagnosis
is crucial for those with symptoms, especially in remote, vulnerable communities
provide a broad portfolio of tests for high-transmission settings
Silent malaria carriers—those without symptoms but still spreading the disease—pose serious risks, especially to pregnant women, leading to low birth weight or miscarriage.2,6 Innovative diagnostics are essential. New high-sensitivity tests detect asymptomatic carriers better than traditional RDTs, offering added protection for vulnerable populations.5
In the fight against malaria, the insights and experiences of experts on the front lines are invaluable. These voices of change highlight the critical role of innovative diagnostics and the importance of addressing both symptomatic and asymptomatic cases. By sharing their perspectives, these leaders underscore the necessity of high-quality RDTs and next-generation tools to move towards malaria elimination.
“Diagnosis is crucial. It will save us a lot of costs in the long run. It is key in demonstrating results.”
Olugbenga Ayodeji Mokuolu, MBBS, MBA, MD, FWACP (Paed), FAMedS
Professor of Paediatrics and Child Health
College of Health Sciences, University of Ilorin/Teaching Hospital, Nigeria
“We need to introduce new tools in case you are facing some asymptomatic people that are not treated on time that sustain a malaria infection. This is missing an opportunity to eliminate malaria nationwide, but also at the global level.”
Aimable Mbituyumuremyi, MD, MSc
Malaria Program Manager
Rwanda Biomedical Centre
“No single malaria case should be left behind. So we need to develop tools that are able to pick all of those cases so that we move towards elimination.”
Agaba Bosco, PhD, MSc, MPH, BMLS
National Coordinator for Malaria Diagnostics National Malaria Program, Uganda
Our bold vision: A malaria-free world
Malaria burdens vulnerable communities and fuels inequality. With innovation and partnership, we can change that. Success demands ongoing effort to leave no one behind. Let’s work together to realize this vision and unlock the limitless possibilities of a malaria-free world.
Our bold vision: A malaria-free world
Malaria burdens vulnerable communities and fuels inequality. With innovation and partnership, we can change that. Success demands ongoing effort to leave no one behind. Let’s work together to realize this vision and unlock the limitless possibilities of a malaria-free world.
A LEADER IN RAPID POINT-OF-CARE DIAGNOSTICS.
©2025 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.
Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement.
Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.
Abbott - A Leader in Rapid Point-of-Care Diagnostics.
